The SRNE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SRNE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SRNE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SRNE Detailed Price Forecast - CNN Money||View SRNE Detailed Summary - Google Finance|
|View SRNE Detailed Summary - Yahoo! Finance||View SRNE Stock Research & Analysis - Zacks.com|
|View SRNE Trends & Analysis - Trade-Ideas||View SRNE Major Holders - Barrons|
|View SRNE Call Transcripts - NASDAQ||View SRNE Breaking News & Analysis - Seeking Alpha|
|View SRNE Annual Report - CompanySpotlight.com||View SRNE OTC Short Report - OTCShortReport.com|
|View SRNE Fundamentals - TradeKing||View SRNE SEC Filings - Bar Chart|
|View Historical Prices for SRNE - The WSJ||View Performance/Total Return for SRNE - Morningstar|
|View the Analyst Estimates for SRNE - MarketWatch||View the Earnings History for SRNE - CNBC|
|View the SRNE Earnings - StockMarketWatch||View SRNE Buy or Sell Recommendations - MacroAxis|
|View the SRNE Bullish Patterns - American Bulls||View SRNE Short Pain Metrics - ShortPainBot.com|
|View SRNE Stock Mentions - StockTwits||View SRNE Stock Mentions - PennyStockTweets|
|View SRNE Stock Mentions - Twitter||View SRNE Investment Forum News - Investor Hub|
|View SRNE Stock Mentions - Yahoo! Message Board||View SRNE Stock Mentions - Seeking Alpha|
|View Insider Transactions for SRNE - SECform4.com||View Insider Transactions for SRNE - Insider Cow|
|View SRNE Major Holdings Summary - CNBC||View Insider Disclosure for SRNE - OTC Markets|
|View Insider Transactions for SRNE - Yahoo! Finance||View Institutional Holdings for SRNE - NASDAQ|
|View SRNE Stock Insight & Charts - FinViz.com||View SRNE Investment Charts - StockCharts.com|
|View SRNE Stock Overview & Charts - BarChart||View SRNE User Generated Charts - Trading View|
Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018
Posted on Wednesday September 19, 2018
Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (SRNE) (Sorrento), today announced that the Wholesale Acquisition Cost (WAC) for ZTlido™ (lidocaine topical system) 1.8% (ZTLIDO) is $8.98 per patch and is now listed in pricing compendia. Post-herpetic neuralgia (PHN), also referred to as post-shingles pain, is a frequent complication of shingles, a condition caused by the herpes zoster (HZ) virus, which afflicts an estimated 1 million people each year in the US.
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
Posted on Monday September 10, 2018
Sorrento Therapeutics, Inc. (SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”), closed a debt financing with leading global institutional investors for aggregate gross proceeds to Scilex of $140 million. Scilex intends to use the net proceeds from this transaction for working capital and general corporate purposes in respect of commercialization of ZTlido™ (lidocaine topical system) 1.8%. Morgan Stanley & Co. LLC acted as sole structuring agent for the transaction. “This non-dilutive financing provides Scilex with the capital resources to successfully execute on the launch of ZTlido,” said Henry Ji, Chairman, President and Chief Executive Officer of Sorrento and Scilex.
Scilex Presents ZTlido™ Data on Superior Adhesion over Lidocaine Patch Formulation
Posted on Friday September 07, 2018
- Data Presented at PAINWeek® Also Showed ZTlido Was Well-Tolerated and Demonstrated Bioequivalence to Lidoderm® Patch1,2 - Study Results Make Strong Case for ZTlido as Non-Opioid Treatment for Post-Shingles ...
Research Report Identifies Brady, Akari Therapeutics, MTGE Investment, Jones Lang LaSalle, New Relic, and Sorrento Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
Posted on Tuesday September 04, 2018
NEW YORK, Sept. 04, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...